First-line Pembrolizumab for Advanced Lung Cancer
Author Information
Author(s): Piedra Aida, Martínez-Recio Sergio, Hernández Ainhoa, Morán Teresa, Arriola Edurne, Recuero-Borau Jordi, Cobo Manuel, Cordeiro Patricia, Mosquera Joaquín, Fernández Manuel, García-Campelo Rosario, Calles Antonio, Álvarez Rosa, Zapata-García María, Isla Dolores, Callejo Ana, Iranzo Patricia, Serra-López Jorgina, Barba Andrés, Sullivan Ivana, Felip Enriqueta, Majem Margarita
Primary Institution: Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hypothesis
What are the real-world outcomes of patients with advanced non-small cell lung cancer and high PD-L1 expression receiving first-line pembrolizumab therapy?
Conclusion
Corticosteroid treatment and poor ECOG-PS are negative predictive factors for first-line pembrolizumab monotherapy in patients with advanced high PD-L1 NSCLC.
Supporting Evidence
- Among the 494 included patients, the median overall survival was 15.9 months.
- Patients with ECOG-PS 0 had a median OS of 36.7 months compared to 14.8 months for ECOG-PS 1.
- 44% of patients were exposed to corticosteroids, which negatively impacted their median OS.
Takeaway
This study looked at patients with advanced lung cancer who received a specific treatment and found that some factors, like taking steroids, can make the treatment less effective.
Methodology
A multicenter retrospective analysis of patients treated with first-line pembrolizumab, evaluating clinical outcomes based on various factors.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study's retrospective design may introduce selection bias, and data collection could vary between institutions.
Participant Demographics
Median age was 67.3 years, 77% male, with 54% former smokers and 38% current smokers.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 13.1 to 18.8 for OS, 95% CI 7.7 to 12.1 for PFS
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website